CN1283693A - Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB - Google Patents
Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB Download PDFInfo
- Publication number
- CN1283693A CN1283693A CN00121027A CN00121027A CN1283693A CN 1283693 A CN1283693 A CN 1283693A CN 00121027 A CN00121027 A CN 00121027A CN 00121027 A CN00121027 A CN 00121027A CN 1283693 A CN1283693 A CN 1283693A
- Authority
- CN
- China
- Prior art keywords
- sequence
- polypeptide
- cklf
- polynucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000007365 immunoregulation Effects 0.000 title abstract description 5
- 230000006870 function Effects 0.000 title description 14
- 230000000638 stimulation Effects 0.000 title description 4
- 230000003394 haemopoietic effect Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
- 229920001184 polypeptide Polymers 0.000 claims abstract description 63
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 42
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 12
- 239000012190 activator Substances 0.000 claims abstract description 6
- 230000002607 hemopoietic effect Effects 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 239000002773 nucleotide Substances 0.000 claims description 46
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 108091033319 polynucleotide Proteins 0.000 claims description 32
- 102000040430 polynucleotide Human genes 0.000 claims description 32
- 239000002157 polynucleotide Substances 0.000 claims description 32
- 238000001890 transfection Methods 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000026278 immune system disease Diseases 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 37
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 abstract 1
- 108700032141 ganirelix Proteins 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 62
- 108020004414 DNA Proteins 0.000 description 29
- 150000001413 amino acids Chemical group 0.000 description 25
- 108090000695 Cytokines Proteins 0.000 description 20
- 102000004127 Cytokines Human genes 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 210000003527 eukaryotic cell Anatomy 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 108091060211 Expressed sequence tag Proteins 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 102220023257 rs387907546 Human genes 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000002798 bone marrow cell Anatomy 0.000 description 7
- 102220369445 c.668T>C Human genes 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 102100039550 Chemokine-like factor Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 101150076489 B gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 101710204213 Chemokine-like factor Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000888518 Homo sapiens Chemokine-like factor Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003995 blood forming stem cell Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000014107 chromosome localization Effects 0.000 description 2
- 238000003200 chromosome mapping Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 108010004073 cysteinylcysteine Proteins 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007030 peptide scission Effects 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 101000946068 Caenorhabditis elegans Ceramide glucosyltransferase 3 Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 101150012763 endA gene Proteins 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 101150085823 hsdR gene Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses a new cell factor CKLF-HIA and its variant CKLF-HIB, their nucleic acid sequences and amino acid sequences, the carrier of their nucleic acid sequences, the host cell for expressing them and a method for preparing their polypeptides by gene engineering. The medicinal composition containing them and their antibody, antagon and activator are also disclosed. Said cell factors can be used for treating the diseases in hemopoietic system and immune system as they have he mopeitic stinulation activity and immunoregulation action.
Description
The present invention relates to bioengineering field, specifically nucleic acid coding sequence and the aminoacid sequence of new cytokine CKLF-H1A and varient CKLF-H1B thereof, carry the carrier of CKLF-H1A, B nucleotide sequence, express the host cell of CKLF-H1A, B, the pharmaceutical composition that contains CKLF-H1A, B, the antibody of CKLF-H1A, B and antagonist, and cytokine CKLF-H1A, the B purposes in the pharmaceutical composition of preparation treatment disease of hematopoietic system and disease of immune system.
Cytokine by the synthetic justacrine of body inner cell, participate in the proliferation and differentiation of various kinds of cell, the general name of the micromolecule polypeptide that in the physiology of body and pathologic process, plays a significant role.Cytokine comprises interleukin-, G CFS, Interferon, rabbit, tumour necrosis factor, somatomedin and chemokine etc.Different physiological roles such as cytokine has: they can regulate body's immunological function, participate in propagation and the differentiation of hemopoietic stem cell, promote vascular endothelial cell proliferation and new vessel generation, also significant aspect antitumor and anti-microbial infection.In recent years, continuous development along with Protocols in Molecular Biology, the structure function of people's pair cell factor and acceptor thereof, the signal conduction and the expression regulation of cytokine have had more deep understanding, it is clinical to utilize the cytokine of genetic engineering technique production reorganization or its antagonist to be used for as medicine, and obtains good efficacy.For example marrow sample hemopoietic progenitor cell supressor (MPIF-1) as the heavy dose that the hematopoiesis protective material is used to tumour put, in the chemotherapy; be expected to become biotechnology medicine (the Marshall A of a new generation; HGS Launches " first " genomics product in clinic.NatBiotechnol 1998,16:129).This prompting cytokine has broad application prospects in the treatment of difficult and complicated illness such as tumour, hematopoietic disorder disease, autoimmune disorder.
Cytokine CKLF-H1A, B (Chemokine Like Factor Homologue 1A, B, be called for short CKLF-H1A, B) gene be that the inventor finds that by analyzing expressed sequence tag (EST) nucleotide sequence of this gene and known does not have tangible homology.The inventor in protokaryon and eukaryotic cell, successfully expressed this polynucleotide encoding CKLF-H1A, B polypeptide.
First purpose of the present invention provides the polynucleotide sequence of Codocyte factor CKLF-H1A, B.
Second purpose of the present invention provides the carrier that has CKLF-H1A, B nucleotide sequence.
The 3rd purpose of the present invention provides carrier transfection, conversion through carrying CKLF-H1A, B nucleotide sequence or the host cell of transduceing.
The 4th purpose of the present invention provides the method for producing CKLF-H1A, B mature polypeptide with genetic engineering means.
The 5th purpose of the present invention provides the aminoacid sequence of cytokine CKLF-H1A, B.
The 6th purpose of the present invention provides the pharmaceutical composition that contains CKLF-H1A, B.
The 7th purpose of the present invention provides mono-clonal or the polyclonal antibody of CKLF-H1A, B.
The 8th purpose of the present invention provides the antagonist of CKLF-H1A, B.
The 9th purpose of the present invention provides the activator of CKLF-H1A, B
The of the present invention ten purpose provides CKLF-H1A, B and has purposes in the pharmaceutical composition of hemopoinesis stimulating activity and immunoregulation effect in preparation.
The present invention realizes by the following technical solutions.The inventor has found the gene (seeing Chinese patent 99107284.7 for details) of chemokine-like factors (CKLF-1) by the inhibition hybridization technique (SSH) of successively decreasing.Contriver and then classify the basis as with the nucleotides sequence of CKLF-1, carry out expressed sequence tag (Expression Sequence Tag by EST Assembly machine (network address is http://www.tigenm.it), be called for short EST) analyze, obtained the cDNA sequence of total length 700bp, increase from normal people's cDNA library by design specificity upstream primer P1 (5 '-GCG ATC CAA AGA GCG CGT-3 ') and downstream primer P2 (5 '-TCT CGA TAA AAGCAG CAG CCC-3 '), separation also clones cytokine CKLF-H1A, the gene of B (Chemokine Like Factor Homologue 1A, B is hereinafter to be referred as CKLF-H1A, B).By retrieval, the nucleotide sequence of CKLF-H1 is new sequence.
According to a first aspect of the invention, the invention discloses CKLF-H1A and nucleotide sequence CKLF-H1B.CKLF-H1A and CKLF-H1B encode respectively and have the mature polypeptide of 149 amino acid (Aa) and 94 amino acid (Aa), respectively shown in SEQ ID NO:2 and SEQ ID NO:4.The mature polypeptide of SEQ ID NO:1 coding has the expressed aminoacid sequence of DNA among the culture presevation CGMCC NO.0456.1; The mature polypeptide of SEQ ID NO:3 coding has the expressed aminoacid sequence of DNA among the culture presevation CGMCC NO.0456.2.
The nucleotide sequence of CKLF-H1A shown in SEQ ID NO:1,603 Nucleotide of its total length, encoding sequence is a 1-450 position Nucleotide.The nucleotide sequence of CKLF-H1B shown in SEQ ID NO:3,587 Nucleotide of total length, encoding sequence is a 1-285 position Nucleotide.Except that 16 Nucleotide of disappearance, other sequence of CKLF-H1B (SEQ ID NO:3) is identical with the sequence (SEQ ID NO:1) of CKLF-H1A, 16 Nucleotide of disappearance are equivalent to the 280-295 position of SEQ ID NO:1, the appearance of disappearance causes occurring terminator codon in advance among the SEQ ID NO:3 the corresponding generation difference of the two encoded protein product.Therefore, SEQ ID NO:3 is the special shape of SEQ ID NO:1, and the generation of difference may be that shear histories different in the same tissue causes.
Nucleotide sequence of the present invention can be DNA or RNA, and wherein DNA comprises cDNA, genomic dna and synthetic DNA, and DNA can be two strands or single stranded form, and single stranded DNA can be coding strand or noncoding strand (antisense strand).
The nucleotide sequence of described cytokine CKLF-H1A, B preferably provides with unpack format, isolated nucleic acid sequences can include only the encoding sequence of mature polypeptide, the encoding sequence and the additional code sequence that also can comprise mature polypeptide, the encoding sequence and the non-coding sequence that can also comprise mature polypeptide, for example intron, encoding sequence 5 ' or the non-coding sequence of 3 ' end etc.The encoding sequence of CKLF-H1A, B can be entirely identical to the encoding sequence shown in SEQ ID NO:1 or the SEQ ID NO:3, or (the bacterial strain title in the culture presevation proof is CKLF-H1 (12) to be same as the bacterial strain that preserving number is CGMCCNO:0456.1, corresponding to CKLF-H1A) or preserving number be the encoding sequence that recombinant chou carries in the bacterial strain (the bacterial strain title in the culture presevation proof is CKLF-H1 (18), corresponding to CKLF-H1B) of CGMCC NO:0456.2.Owing to the degeneracy of genetic code, it can be different from the sequence shown in SEQ ID NO:1 or the SEQ ID NO:3, the perhaps entrained encoding sequence of preservation thing in addition.
The invention further relates to coding with shown in the SEQ ID NO:2 more than more than peptide or the recombinant chou coding that carries with preservation strain CGMCCNO.0456.1 peptide have nucleic acid fragment, analogue and derivative, and the varient of above-mentioned polynucleotide of same acid sequence.The varient of polynucleotide can be the different varients of shearing varient or non-natural existence of naturally occurring allelic variation body, mRNA.Varient also can be deletion mutation body, replacement varient and adding (insertion) varient that coding and polypeptide shown in the SEQ ID NO:2 have the polypeptide of same or similar biologic activity.Said allelic variant can have Nucleotide and replace, inserts or add, but do not change in fact coded more than the alternative form of polynucleotide of function of peptide.CKLF-H1B of the present invention (SEQ ID NO:3) promptly belongs to this type of varient.CKLF-H1A varient by the nucleotide coding of these variations can be identical with CKLF-H1A of the present invention on function, similar or different.
Can use the hybridization probe of the small segment of full-length gene of the present invention, to separate the overall length gene from the cDNA library and the highly nucleotide sequence of sequence homology to be arranged with CKLF-H1A of the present invention, B gene as the cDNA library.These probes generally have 30 bases at least, also can contain the nearly base more than 50.Can identify the cDNA clone who is equivalent to the overall length transducer and contains the genomic clone of complete genome with these probes.Method comprises according to the known dna sequence synthetic oligonucleotide probe, and under hybridization conditions, use the oligonucleotide contain with the mark of the dna sequence dna of gene complementation of the present invention to hybridize with people cDNA genomic dna or RNA storehouse, therefrom isolate in the library and the needed nucleotide sequence of probe hybridization.
The gene order that the invention still further relates to CKLF-H1A, B has 70% at least, and is better 90%, the polynucleotide sequence of best 95% homology.Be particularly related under stringent condition the polynucleotide with above-mentioned CKLF-H1A, B gene recombination, said " stringent condition " means the prerequisite that hybridization takes place is to possess 95% homology between sequence at least.Such sequence can be natural existence or artificial the generation, can comprise the allelic variation body of CKLF-H1A, B nucleotide sequence, also can comprise disappearance, insertion and the displacement of base in the CKLFH1 nucleotide sequence.The polypeptide of such sequence encoding can be identical with CKLF-H1A of the present invention, B on function, similar or different, but preferably coding and CKLF-H1A, the essentially identical polypeptide of B biologic activity.
According to a second aspect of the invention, the invention discloses the carrier that carries above-mentioned polynucleotide, said polynucleotide can be inserted into the various suitable expression vectors that are used for expressing this polypeptide.Such carrier comprises that karyomit(e), non-chromosome are originated or the synthetic dna sequence dna, the for example derivative of SV40, bacterial plasmid, phage DNA, yeast plasmid, phage (by plasmid and phage DNA molectron deutero-carrier) and virus (as baculovirus, vaccinia virus, adenovirus, domestic animal poxvirus) DNA, condition is that these carriers can duplicate in selected host cell and survive.
Available various known method is inserted into suitable dna sequence dna in the suitable restriction endonuclease site of carrier.Being inserted into dna sequence dna in the expression vector, to be operably connected to suitable expression control sequenc be promotor, synthetic to instruct mRNA.The example of such promotor comprises RSV, HIV, CMV or SV40 promotor, intestinal bacteria 1ac or trp promotor, phage PL promotor and other promotors that controlling gene is expressed in protokaryon or eukaryotic cell or its virus.
In addition, expression vector can contain ribosome bind site and the transcription terminator that starts translation, and contain one or more selected marker genes, to provide by the phenotypic characteristic selected of the host cell of conversion, as be applicable to eukaryotic neomycin resistance or dihydrofolate reductase gene, or be applicable to penbritin or tetracycline resistance gene in the intestinal bacteria.
In case of necessity, for the DNA that improves code book invention polypeptide transcribes efficient in higher eucaryotic cells, can in carrier, insert enhancer sequence.Enhanser generally is to contain 10-300 base pair approximately and act on promotor to strengthen the cis-acting elements that DNA transcribes.In addition, also can instruct translation product excretory leader sequence (secretion signal) in pericentral siphon or extracellular substratum in case of necessity in one of insertion between promotor and the downstream configurations sequence.Perhaps, can import the allogeneic dna sequence of encoding fusion protein matter as required, said fusion rotein can comprise that is given a required feature, as is used for stable not held identification polypeptide by the N product of expression or that simplify its purification step.
Specifically, but be applicable to that the commercially available expression vector of prokaryotic cell prokaryocyte generally all has selection marker and cellular replication initial point, have bacterium promotors such as lacI, T7, λ PL and trp, and other genetic elements of known cloning vector pBR322 (ATCC37017).Commercially available carrier like this comprises pGEM (Promega) and pKK223-3 (Pharmacia).Can select to be derived from the suitable carrier of pBR322 according to selected suitable promotor and structural gene sequence to be expressed.Be applicable to that eukaryotic carrier has eukaryotic cell promotor such as CMV, SV40 etc., such carrier comprises pMT-hIL-3 (horse big dragon, Di Chunhui, Pang Jian etc. (1991) hi-tech communication 11:26-29), pQE-9 (Qiagen), pD10, pNH18A (Stratagene), pKK233-3, pDR540, pRIT5 (Pharmacia), and pcDNA3, pCI, pWLNEO, pSG (Stratagene), pSVL (Pharmacia).
In a word; the present invention relates to comprise the recombinant chou of CKLF-HIA and CKLF-HIB nucleotide sequence; recombinant chou comprises the various carriers that inserted nucleotide sequence of the present invention forward or backwards; as plasmid, virion or phage, and in adjusting sequence such as promoter sequence and the enhancer sequence that it is suitable that the upstream of said polynucleotide sequence has been operably connected.Mammalian expression vector can contain replication origin, transcription termination sequence, and 5 ' flank non-coding sequence.Can use the dna sequence dna in the shearing that is derived from SV40 and polyadenylation site that necessary genetic elements is provided.
According to a third aspect of the present invention, the invention provides cloning vector or expression vector transduction, conversion or transfection appropriate host cell through carrying polynucleotide of the present invention, methods known in the art comprise calcium chloride infection protocol, liposome transfection method, electroporation or microprojectile bombardment methods etc.In order to activate promotor, to select transformant or the required CKLF-H1A that increases, B gene, can in the conventional nutritional medium of suitably modifying, cultivate by transduction, transfection or transformed host cells.Culture condition such as employed temperature, pH generally all are by the decision of the host cell of selected expression specified protein in the cultivation, and these conditions all are well known to those skilled in the art.
Can use any appropriate host cell to express polynucleotide of the present invention, the suitable host's that can mention example has: bacterial cell such as intestinal bacteria, genus bacillus, streptomycete etc.; Low eukaryotic cell such as the yeast cell of waiting; Insect cell such as fruit bat and fortunatus cell; Higher eucaryotic cells such as mammalian cell such as CHO, COS cell.The example of mammalian expression system comprises the human cell line, as Hela, 293 and U937 clone, and COS, CHO and bhk cell system.
The 4th aspect of the present invention discloses with DNA recombinant technology production the present invention has the method for the polypeptide of immunoregulatory activity and hematopoietic cell stimulating activity.At transformed host cell and after being grown into suitable cell density,, continue cultivation then with appropriate means (inducing) evoked promoter as temperature variation or chemical speciality by transformed host cells.After cultivation is finished, available centrifuging collecting cell, and with any known method, as freeze-thaw method, supersound process method, N,O-Diacetylmuramidase dissolution method or mechanical crushing method smudge cells.Can reclaim from the host cell culture and purifying CKLF-H1A of the present invention, B and varient polypeptide thereof with various known methods, these methods comprise ammonium sulfate or ethanol precipitation, acid extraction method, ultrafiltration process, ion exchange chromatography, phosphoric acid fiber chromatography, hydrophobic interaction chromatography method, gel filtration method, affinity chromatography and high pressure fluid column chromatography.
Can biological engineering method routinely produce polypeptide product by the coding of the recombinant DNA sequence in the host cell.Also can use conventional peptide synthesizer chemosynthesis polypeptide of the present invention.Perhaps can use the mRNA that is derived from DNA construct of the present invention, in cell free translation system, produce required protein.
According to a fifth aspect of the present invention, the invention provides the aminoacid sequence of CKLF-H1A, B mature polypeptide, CKLF-H1A, B have multi-form mature polypeptide, have 149 Aa and 94 Aa respectively as SEQ ID NO:2 and SEQ ID NO:4.
Utilize RT-PCR technology for detection CKLF-H1A, B expression at different tissues, find that CKLF-H1A, B have special express spectra, in various kinds of cell, all have low abundance to express, but in people's testis library special high expression level, and different varient forms is arranged, as CKLF-H1B.To clone and 94 amino acid of its coding of sequential analysis proof of varient gene, called after CKLF-HB, this varient are likely the different shear-forms of CKLF-H1A gene.
Amino acid sequence analysis shows that CKLF-H1A, B and other known cytokine do not have homology.With the aminoacid sequence that the Prosite computer software analysis is inferred, do not find tangible transmembrane domains sequence, there are not DNA binding site and N-glycosylation site.The 22-23 amino acids of the N end of SignalP V2.0 software analysis proof CKLF-H1A contains natural signals peptide cleavage site.The activation analysis proof CKLF-H1A of eukaryotic cell expression supernatant liquor, B albumen can be secreted into the extracellular, belong to secreted protein.Contain the Cys-Cys constitutional features of (being called for short the CC structure) in the amino acid structure of SEQ ID NO:2, SEQ ID NO:4 does not then possess the CC structure.
The invention still further relates to CKLF-H1A, B and have same or analogous biologically active polypeptides fragment.Polypeptide of the present invention can be natural generation, chemosynthesis or be produced by protokaryon or eukaryotic cell with the DNA recombinant technology.The polypeptide that preferred reorganization produces.
According to a sixth aspect of the invention, CKLF-H1A of the present invention, B and activeconstituents thereof can mix with pharmaceutical compositions mutually with one or more pharmaceutically acceptable carriers or vehicle.Can pharmaceutical composition be made multiple formulation according to the needs of therapeutic purpose, route of administration, for example solution, liposome agent, microcapsule and other sustained release preparations.The example of carrier or vehicle comprise physiological saline, etc. ooze the combination of glucose solution, buffer saline, glycerine, ethanol and above-mentioned solution.Can in composition, add as required and assist: for example synergistic compound be arranged with CKLF-H1A of the present invention, B; And for example human serum albumin, low molecular weight peptide, amino acid (as glycine or Methionin) and metallic cation are (as Zn
2+, Mn
2+, Mg
2+And Ca
2+) wait protein protective agent; Stablizers such as polyoxyethylene glycol, carboxymethyl cellulose, polyglycine, gsh; Proteinase inhibitor and free-radical scavengers; And under the situation of mucous membrane or local skin administration, add skin penetrants such as dimethyl sulfoxide (DMSO) or laurocapram.
For the convenience on using be convenient to keep the biologic activity of the special primary activity composition of each composition of composition, can be with the special packaged form that makes medicine box of drug regimen of the present invention, such medicine box can comprise one or more containers that one or more compositions of pharmaceutical composition of the present invention are housed, and indicates the use of relevant medicine or the lot number and the relevant information of sale by the specified form of pharmacy administration of government on each container.
Can pass through the outer approach of conventional route, particularly gi tract and use administration of the present invention.The effective dosage ranges of pharmaceutical composition of the present invention can be from several micrograms to several milligrams/kg body weight/sky, but should be determined by the clinician according to factors such as age of the character of disease to be treated or pathological state and severity, patient, body weight, general health situation administering modes at the concrete dosage of each given patient.
Also can express polypeptide of the present invention in vivo, promptly use these polypeptide with so-called " gene therapy " method according to the present invention.For example, can handle patient's cell in the outer-gene through engineering approaches, and then cell that will be engineered imports in the patient body that desire treats with said polypeptide with the polynucleotide of code book invention polypeptide.For example can use the RNA counter-transcription-ing virus particle that contains code book invention polypeptide to come transfection and engineered said cell of expressing polypeptide of the present invention in vivo.Can the production cell that generation contains the counter-transcription-ing virus particle of code book invention polypeptide be come into operation in the patient body by currently known methods, carry out genetically engineered transformation and express said polypeptide in vivo with pair cell in vivo.
Above-mentioned these methods and be used for these methods retrovirus, be included in carry intravital suitable promotor, comprise promotor and be in nucleotide coding sequence more than the suitable promotor control down carrier, be used for the transfection package cell line forming the retroviral plasmid vector of production clone, and suitable packing cell that can be transfected all is known in the field of gene.
Can by various known methods with the carrier of the nucleic acid coding sequence that carries polypeptide of the present invention transfection packing cell or target cell in the external or body.These methods comprise but are not only limited to electroporation, microparticle bombardment (for example using the Biolistic device), liposome transfection method, and really calcium phosphate precipitation method or these methods unite use.In addition, also retrovirus vector can be wrapped in the liposome, perhaps be coupled on the liposome, and then be transported in the suitable target cell of host.
In a word, can produce the infectious retrovirus carrier granule of the nucleic acid coding sequence comprise polypeptide of the present invention, use such carrier granule host eukaryotic cell of in external or body, transduceing then by production clone.The eukaryotic cell of being transduceed will be expressed the nucleotide sequence of the said polypeptide of coding.The eukaryotic cell that can be changeed comprises but is not only limited to embryonic stem cell, embryo cells and becomes human cancer cell, and hemopoietic stem cell, liver cell, inoblast, sarcoplast, mesenchymal cell, epithelial cell and epidermic cell.
The invention still further relates to and use polynucleotide of the present invention, detect the gene of mutant form and express deficiency or express excessive disease that is caused or pathological state because of CKLF-H1A, B in the body with diagnosis as diagnostic reagent.
Available various technology detects the individuality that carries CKLF-H1A, B transgenation on dna level.Can be from patient's body fluid, as obtaining being used for the nucleic acid of diagnostic test in blood, urine, saliva or live body or the postmortem material.Can use gene DNA or RNA directly to detect, detect again after also can using PCR method (Saiki etal., Nature 324:163-166,1986) DNA amplification.For example, can use the sudden change of identifying and analyze corresponding gene in the material to be checked with the nucleic acid complementary PCR primer of code book invention polypeptide, as comparing with normal genotype and changing to determine the disappearance or the insertion of gene to be checked according to the size of amplified production.Can be with DNA and radiolabeled CKLF-H1A, B and the varient RNA or the antisense dna sequence hybridization of amplification, to identify point mutation.
Available direct dna sequencing method is analyzed with reference to the sequence difference between gene and the mutator gene.In addition, the dna fragmentation that also can utilize the clone detects specific dna fragmentation as probe and in conjunction with PCR method with hypersensitivity and specificity, for example can unite the strand PCR product or the single-stranded template molecule that use sequencing primer and produced by amplification PCR products.
Can be at the gel that contains or do not contain denaturing agent, the electrophoretic mobility that particularly detects DNA in the high resolving power gel is finished the genetics test based on dna sequence dna difference.Can on sex change methane amide gradient gel, distinguish not homotactic dna fragmentation (as referring to Myers et al., Science 230:1242,1985).In addition, also available nucleic acid enzyme protection detection method or chemical cracking method (as referring to Cotton et al., PNAS, USA, 85:4397-4401,1985) disclose the sequence change of privileged site.
The invention still further relates to the diagnostic test method that CKLF-H1A, B in the various tissues and varient protein level thereof change that detects.It is well known by persons skilled in the art being used for detecting CKLF-H1A, the B of the interior sample of host-derived body and the detection method of varient protein level thereof, and comprises radioimmunology, competitive combined techniques, Western engram analysis method and enzyme-linked immunosorbent assay (ELISA).Wherein preferable methods is the ELISA method.
Polynucleotide sequence of the present invention identifies it also is valuable for karyomit(e).This sequence can be positioned the chromosomal specific position of one or two people specifically and can hybridize with it.According to the present invention, this bright DNA is carried out first important step that chromosome mapping connects these sequences and disease related gene.
Can prepare the PCR primer to carry out the chromosome mapping of sequence from cDNA.3 ' translation district to gene carries out Computer Analysis, thereby crosses over an above exon in the genomic dna and add primer in the amplification procedure to select rapidly.Use these primers to contain the chromosomal somatic cell hybrid of one or two people then with the screening of PCR method.Have only those hybrids that contain corresponding to the Human genome of primer just to produce the fragment of amplification.It is a kind of facilitated method of specifying the position of specific DNA on specific karyomit(e) that somatic cell hybrid is carried out the PCR mapping.Using according to the present invention under the situation of same Oligonucleolide primers, available one group derives from specific chromosomal fragment or big genomic clone colony finishes inferior location by similarity method.And then cDNA clone is carried out accurate chromosomal localization (referring to Verma et al., Humanchromosomes:A Manual of Basic Techniques, Pergamon Press, NY (1988)) with fluorescent in situ hybridization method (FISH).
In case finished the accurate chromosomal localization mapping of sequence, the physical location and the genetic map data of this sequence can have been connected.Identify that by linkage analysis (the common heredity of the adjacent gene of physics) mapping is positioned gene on the same chromosomal region and the relation between the disease then.Then, can determine impaired or the difference of the cDNA between injured individual or genomic dna not.If in some or all injured individual, observe sudden change, and do not observe this sudden change in the normal individual, just then this sudden change is likely paathogenic factor.
According to a seventh aspect of the present invention, can be with CKLF-H1A of the present invention, B polypeptide and fragment, analogue or derivative as the immunogen preparing corresponding antibody.Antibody can be polyclone or monoclonal antibody, can be chimeric, strand or humanized antibody and Fab fragment thereof.Can produce human monoclonal antibodies with hybridoma technology, can prepare humanized antibody with transgenic mice.
According to an eighth aspect of the present invention, the present invention relates to block or closing cell's factor CKLF-H1A, the active CKLF-H1A of B, B antagonist.Antagonist can combine with one or more pharmaceutically acceptable carrier, vehicle or auxiliary material and form pharmaceutical composition.
According to a ninth aspect of the present invention, the present invention relates to can active cells factor CKLF-H1A, the active CKLF-H1A of B, the B activator.Activator can combine with one or more pharmaceutically acceptable carrier, vehicle or auxiliary material and form pharmaceutical composition.
According to a tenth aspect of the present invention, the invention discloses cytokine CKLF-H1A, the B purposes in the pharmaceutical composition of preparation treatment hemopoietic system and disease of immune system.The biologic activity experiment shows CKLF-H1A of the present invention, B polypeptide as a kind of secretion small-molecule substance, and people and bone marrow cells in mice are had obviously short proliferation function, and mouse thymus and splenocyte are also had the obvious stimulation effect, sees embodiment six for details.
Retrieval shows that the nucleotide coding sequence of cytokine CKLF-H1A, B is one section new sequence.CKLF-H1A, B do not have homology at amino acid levels and known cytokine, with CKLF1 20% homology are arranged.Experimental results show that cytokine CKLF-H1A, B can promote mouse bone marrow cells, thymus gland and splenocyte and human bone marrow cell's propagation, the eukaryotic cell expression albumen of CKLF-H1A, B does not show chemotaxis, and the chemokine-like factors CKLF1 with similar functions has the chemotactic activity of wide spectrum.Because chemotaxis often causes inflammatory reaction, thereby CKLF-H1A, B have more value for clinical application, is expected to bring into play significant role in the treatment of hemopoietic system and disease of immune system.
In order more to be expressly understood essence of the present invention, referring now to following drawings and Examples it is made an explanation, the purpose of drawings and Examples does not just limit the present invention in any way for explanation.
The accompanying drawing summary
Fig. 1 is the structure synoptic diagram of prokaryotic expression carrier pMTY4-CKLF-H1A, B.
Fig. 2 is the result that CKLF-H1A expresses in prokaryotic cell prokaryocyte.
Fig. 3 is the structure synoptic diagram of carrier for expression of eukaryon pcDI-CKLF-H1A, B.
Fig. 4 has shown the proliferation function of CKLF-H1A prokaryotic expression protein to bone marrow cells in mice.
Fig. 5 has shown the proliferation function of the transfection supernatant of CKLF-H1A, B to the fetus medullary cell.
Fig. 6 has shown CKLF-H1A, the B transfection supernatant short proliferation function to mouse chest cell.
Fig. 7 has shown the proliferation function of the transfection supernatant of CKLF-H1A, B to mouse boosting cell.
Fig. 8 has shown CKLF-H1A, the B expression in adult's healthy tissues.
Embodiment
Embodiment one, CKLF-H1A, B full length cDNA cloneization
1. analysis of biological information: utilize expressed sequence tag (the ExpressionSequence Tag of CKLF-1 sequence to the people, abbreviation EST) carries out data retrieval and homology relatively, 19 people's est sequences that low homology is arranged have been found, carry out the EST splicing by EST Assembly machine (network address is http://www.tigenm.it), form contig (contig) and carry out the BLAST splicing once more, find complete coding framework.
CKLF-H1A, B full length cDNA cloneization: design of primers: splicing obtains according to EST CKLF-H1A, B full length cDNA sequence, it is as follows to design special primer: upstream primer P1:5 '-GCG ATC CAA AGA GCGCGT-3 ', downstream primer P2:5 '-TCT CGA TAA AAG CAG CAG CCC-3 ' pcr amplification: the testis strand cDNA library of personnel selection is that template is carried out pcr amplification.The PCR product downcuts the PCR band after the agarose gel electrophoresis of TAE preparation separates, add 45 ℃ of-55 ℃ of wash-outs of NaI (6M) of 3 times of volumes, add granulated glass sphere suspension solution 10 μ l, of short duration centrifugation granulated glass sphere-DNA mixture is washed 3 times with washing lotion, adds 45 ℃ of 2-50 ℃ of eluted dnas of H2O.
The PCR product cloning is to pGEM-T Easy carrier: the PGEM-Teasy carrier, purchase company in Promega.The PCR product of purifying is connected to the pGEM-Teasy carrier, connects product and transform XL-1 Blue bacterium, with blue hickie color reaction screening positive clone.
The extraction of plasmid and purifying: the order-checking plasmid carries out purifying with the Tip-20 Mini-preparation test kit of Qiagen company, sequencing kit is available from Pharmacia company, and the specification sheets (seeing Standard Annealing of Primer to Double-Strand Template for details) that provides according to company utilizes ALFExpress II dna sequence analysis instrument to carry out sequencing.
Result: utilize the CKLF-1 sequence people's est database retrieval splicing to be obtained the human cDNA sequence of CKLF-H1A, B total length 700bp.Through RT-PCR increase its coding region and sequential analysis, find that its encoding part is new sequence, shown in SEQ ID NO:1 and SEQ ID NO:3.SEQ ID NO:3 (587 Nucleotide of total length) lacks 16 Nucleotide than SEQ ID NO:1 (603 Nucleotide of total length), and it is the special shape of SEQ ID NO:1.The initial sub-ATG week edge sequence basic symbols of CKLF-H1A, B is closed Kozak rule (GCGATGG) by retrieval, and except that the difference of 16 Nucleotide, the sequence of SEQ ID NO:3 and SEQ ID NO:1 is identical.This difference may be that shear histories different in the same tissue forms.
SEQ ID NO:1 and SEQ ID NO:3 encode respectively and have the mature polypeptide of 149 amino acid (Aa) and 94 amino acid (Aa), respectively shown in SEQ ID NO:2 and SEQ ID NO:4.Aminoacid sequence carries out analysis revealed CKLF-H1A, B and other known cytokine does not have homology.With the aminoacid sequence that the Prosite computer software analysis is inferred, do not find tangible transmembrane domains sequence, there are not DNA binding site and N-glycosylation site.The N end 22-23 amino acids of SignalP V2.0 software analysis proof CKLF-H1A contains natural signals peptide cleavage site.(be called for short the constitutional features of C (structure), SEQ ID NO:4 does not then possess the CC structure to contain Cys-Cys in the amino acid structure of SEQ ID NO:2.
Embodiment two, construction of prokaryotic expression vector
As shown in Figure 1, select pGEM-T-CKLF-H1A, B plasmid that forward inserts, with upstream and downstream primer amplification CKLF-H1A, the B fragment of CKLF-H1A, B, amplification condition is the same.SEQ ID NO:1 is used to increase.Remove the unnecessary VITAMIN B4 " A " of PCR product 3 ' end with the K1enow fragment earlier, cut with the NotI enzyme again, reclaiming the purifying rear clone goes in the pMTY4 carrier (being made up by this chamber) that the StuI-NotI enzyme is cut, plasmid pMTY4-CKLF-H1A, the B that makes up can be in intestinal bacteria the fusion rotein of abduction delivering MS2 and CKLF-H1A, B, between the two by the polypeptide connection at band zymoplasm point of contact.PMTY4-CKLF-H1A, B cut through EcoR I enzyme and discharge CKLF-H1A, B fragment, the sequencing that carries out same as above, and sequencing result is entirely true.
Embodiment three, the CKLF-H1A expression in prokaryotic cell prokaryocyte
(C1857 endA, thi hsdR) are the C600 bacterium that derives to intestinal bacteria pop2136, and the temperature sensitive λ aporepressor of encoding is available from German Bao Ling Man.PMTY4-CKLF-H1A is 30 ℃ of normal cultivations in the pop2136 bacterial strain, 42 ℃ of abduction deliverings.Centrifugal results are induced bacterium, and with the resuspended bacterium of ultrasonic damping fluid of about 1/10 original volume, ultrasonic degradation bacterium, fusion rotein MS2-CKLF-H1A is with the inclusion body formal representation, centrifugal results inclusion body.Inclusion body is at 8M urea, 14mM β-ME, and 37 ℃ of sex change are 30 minutes among the 50M Tris-HCl (pH8.0).By 1: 10 dilution refolding, 4 ℃ were spent the night, and renaturation is carried out zymoplasm simultaneously and cut.Utilize the heparin affinity chromatography post to carry out protein purification.
As shown in Figure 2, the fusion rotein MS2-CKLF-H1A of fusion protein expression vector pMTY4-CKLF-H1A is efficiently expressed in intestinal bacteria, expression amount accounts for 20% of tropina, and albumen is cut the heparin affinity chromatography column purification through sex change renaturation zymoplasm, and purity can reach (Fig. 2) more than 90%.
The structure of embodiment four, eukaryon expression plasmid
Plasmid pCI is available from Promega company, and pcDNA3 is available from Invitrogen company, and plasmid pcDI is that this chamber makes up, and is a carrier for expression of eukaryon that obtains after the BglI-KpnI fragment of pcDNA3 is replaced with the Be1I-KpnI fragment of pCI.As shown in Figure 3, cut with EcoR I enzyme and to discharge CKLF-H1A, B fragment, be connected to it after EcoR I enzyme is cut and handle with CIP after the pCDI carrier in, made up pCDI-CKLF-H1A, B carrier (Fig. 3).
Embodiment five, CKLF-H1A, B change eukaryotic cell over to
The 293rd, HEKC, COS-7 is the green monkey kidney cell that SV40 transforms, cell cultures is in RPM1 1640 substratum that contain 10% foetal calf serum.
Transfection experiment: utilize the efficient transfection reagent of SuperFect (Qiagen company), with the pCDI of purifying, pCDI-CKLF-H1A, B plasmid transfection COS-7 cell, in six orifice plates with 1 * 10
5/ 1.5ml substratum repopulating cell.37 ℃ of CO
2Cultivated 18-24 hour in the incubator, get 2.0 μ g plasmids and add in 100 μ l, 1640 substratum, get 10 μ l SuperFect transfection reagents, add in the DNA mixed solution mixing.It is complete 1640 to get 600 μ l, adds in the transfection reaction mixture.Said mixture is added in the cell, cultivated 2-3 hour.Sucking-off transfection reaction mixture.Add complete 1640 1.5ml, 37 ℃, 5%CO
2Cultivated 48-72 hour.
Stably express clone's acquisition: the stably express clone is behind plasmid transfection 293 cells 72 hours, adds G418 in substratum, and G418 content rises to high density gradually from lower concentration, to 500 μ g/ml, grows cell clone after two weeks.
Six, the proliferation function of CKLF-H1A, B pair cell
1.CKLF-H1A, B is to the short proliferation function of bone marrow cells in mice
Bone marrow cells in mice behind the lysed erythrocyte is taped against in the 96 porocyte culture plates, negative control group adds the normal COS-7 cell conditioned medium of cultivating 72 hours of 10 μ l, and experimental group respectively adds the original content transfection supernatant of CKLF-H1A, B and pCDI respective amount, does 6 multiple holes for every group, 37 ℃, 5%CO
2After cultivating for 2 weeks, add the MTT of 10 μ l 10mg/ml in culture hole, cell continues to spend the night after cultivation added lysate after 6 hours.Measured the absorbance value of 570nm wavelength in second day with microplate reader.Found that (Fig. 4) CKLF-H1A, B transfection supernatant can obviously promote the propagation of bone marrow cells in mice, the pCDI contrast does not have obviously effect.
2.CKLF-H1A, B is to the short proliferation function of people's low density medullary cell
Low density medullary cell after the separation and purification is adjusted into 2 * 10
6/ ml gets 90 μ l and is taped against 96 porocyte culture plates, and negative control group adds normal 293 cell conditioned mediums of cultivating of 10 μ l, and experimental group adds 10 μ l, 293 cell transfecting supernatants, 37 ℃ of 5%CO
2Cultivate 2 weeks added 10 μ l 10mg/ml in culture hole MTT, add lysate after 6 hours and spend the night, the absorbance value of second day survey 570nm wavelength.Found that CKLF-H1A, B can obviously promote the propagation (Fig. 5) of human fetal medullary cell
3.CKLF-H1A, B detects the effect of mouse chest cell and splenocyte
Get normal BALB/C mice 20g, get spleen, thymus gland respectively, obtain mouse thymus and splenocyte, adjusting concentration is 2 * 10
6/ ml gets 90 μ l and is taped against 96 porocyte culture plates, and negative control group adds normal 293 cells and supernatant or the 10 μ l Tris-HCl (50mM pH8.0) that cultivate of 10 μ l; Positive group respectively adds the transfection supernatant of respective amount, pCDI empty carrier, pCDI-CKLF-H1A, the prokaryotic expression protein pMTY-CKLF-H1A of pCDI-CKLF-H1B and purifying, 37 ℃ of 5%CO
2Cultivated for 2 weeks, add 10 μ l 10mg/mlMTT in nutrient solution, cell spends the night after continue cultivating and adding lysate after 6 hours, measures the absorbance value of 570 wavelength in second day with microplate reader.Found that CKLF-H1A, B can promote the propagation of mouse chest cell and splenocyte.(Fig. 6-7)
Embodiment seven, CKLF-H1A, expression level and the shear-form of B in adult's healthy tissues:
Make template with the strand cDNA library that Clontech company Multiple Tissue cDNA Panels test kit provides, utilize CKLF-H1A, B coding region Auele Specific Primer, carry out pcr amplification, amplification condition is as follows, 94 ℃ 2 minutes, 94 ℃, 15 seconds, 58 ℃ 15 seconds, 72 ℃ 30 seconds, 30 circulations, 72 ℃ 7 minutes.Found that (Fig. 8) CKLF-H1A, B all have expression in multiple tissue, but in testis high expression level.Electrophoresis result shows that CKLF-H1A, B have three kinds of different shear-forms.
The sequence table general information
(ⅰ) applicant: Priority Lab. of Medical Immunology, Ministry of Public Health,
Beiyi Lianhe Biological Engineering Co., Beijing
(ⅱ) denomination of invention: cytokine CKLF-H1A and varient CKLF-H1B thereof with hematopoietic stimulation and immunoregulation effect
(ⅲ) sequence number: 4
(ⅳ) address:
(A) contact person: horse big dragon
(B) street: No. 38, College Road, Haidian District
(C) city: Beijing
(D) country: the People's Republic of China (PRC)
(E) postcode: 100083
(ⅴ) computer-reader form:
(A) amboceptor type: 3.5 inches floppy disks
(B) computer: Pentium 166MMX
(C) operating system: WINDOWS 95
(D) software: WORD 97
(ⅵ) telecommunication information:
(A) phone: 86-10-62091149
(B) fax: 86-10-62091149
The information of SEQ ID NO:1
(ⅰ) sequence signature:
(A) length: 603 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: cDNA
(ⅲ) sequence description: SEQ ID NO:1
3 9 15 21 27 33 39 45 ｜ ｜ ｜ ｜ ｜ ｜ ｜ ｜ 1 ATG TTG AAG ATC CTG AGA CTG AGT CTT ATC TTA GGA GCA TTA GCT?46 TGT TTC ATC ATC ACC CAA GCC AAT GAG TCA TTT ATA ACA ATC ACA?91 AGT CTG GAA ATC TGC ATT GTC GTT TTT TTT ATT CTA ATA TAT GTG136 CTA ACC CTT CAC CAC TTG CTG ACC TAT TTA CAT TGG CCC TTA CTT181 GAT CTT ACC AAC AGT ATC ATT ACA GCT GTG TTC CTT TCA GTA GTT226 GCC ATC TTG GCC ATG CAA GAA AAG AAA AGA AGG CAT TTA CTC TAT271 GTC GGG GGG TCC CTG TGT CTC ACA GCG GTA ATC GTG TGT TGC ATC316 GAT GCG TTT GTG GTC ACC ACG AAG ATG AGG ACC AAC TTG AAA AGA361 TTC CTG GGA GTC GAA GTT GAA AGG AAG CTT TCC CCC GCC AAG GAC406 GCC TAC CCC GAA ACC GGC CCC GAC GCC CCG CAG AGG CCC GCC TGA451 AGC CAG CCC GGC GCC CTA GCA GAT GCA CGT GTC TGT CGA ATC GCT496 GCC TCC GAG CCC ACC CCC GAG CTC GCA TGC TGT CAC CCA TTC CAG541 CCT AAA TGT GAC CAT AAA ATT AGG GCT GCT GCT TTT ATC GAG AAA586 AAA AAA AAA AAA AAA AAA
The information of SEQ ID NO:2
(ⅰ) sequence signature:
(A) length: 149 amino acid
(B) type: amino acid
(C) chain: strand
(D) topological framework: linearity
(ⅱ) molecule type: protein
(ⅲ) sequence description: SEQ ID NO:2
5 10 15 | | | 1?Met?Leu?Lys?Ile?Leu?Arg?Leu?Ser?Leu?Ile?Leu?Gly?Ala?Leu?Ala?16?Cys?Phe?Ile?Ile?Thr?Gln?Ala?Asn?Glu?Ser?Phe?Ile?Thr?Ile?Thr?31?Ser?Leu?Glu?Ile?Cys?Ile?Val?Val?Phe?Phe?Ile?Leu?Ile?Tyr?Val?46?Leu?Thr?Leu?His?His?Leu?Leu?Thr?Tyr?Leu?His?Trp?Pro?Leu?Leu?61?Asp?Leu?Thr?Asn?Ser?Ile?Ile?Thr?Ala?Val?Phe?Leu?Ser?Val?Val?76?Ala?Ile?Leu?Ala?Met?Gln?Glu?Lys?Lys?Arg?Arg?His?Leu?Leu?Tyr?91?Val?Gly?Gly?Ser?Leu?Cys?Leu?Thr?Ala?Val?Ile?Val?Cys?Cys?Ile106?Asp?Ala?Phe?Val?Val?Thr?Thr?Lys?Met?Arg?Thr?Asn?Leu?Lys?Arg121?Phe?Leu?Gly?Val?Glu?Val?Glu?Arg?Lys?Leu?Ser?Pro?Ala?Lys?Asp136?Ala?Tyr?Pro?Glu?Thr?Gly?Pro?Asp?Ala?Pro?Gln?Arg?Pro?Ala?---
The information of SEQ ID NO:3
(ⅰ) sequence signature:
(E) length: 587 base pairs
(F) type: nucleic acid
(G) chain: strand
(H) topological framework: linearity
(ⅱ) molecule type: cDNA
(ⅲ) sequence description: SEQ ID NO:3
3 9 15 21 27 33 39 45 ｜ ｜ ｜ ｜ ｜ ｜ ｜ ｜ 1 ATG TTG AAG ATC CTG AGA CTG AGT CTT ATC TTA GGA GCA TTA GCT?46 TGT TTC ATC ATC ACC CAA GCC AAT GAG TCA TTT ATA ACA ATC ACA?91 AGT CTG GAA ATC TGC ATT GTC GTT TTT TTT ATT CTA ATA TAT GTG136 CTA ACC CTT CAC CAC TTG CTG ACC TAT TTA CAT TGG CCC TTA CTT181 GAT CTT ACC AAC AGT ATC ATT ACA GCT GTG TTC CTT TCA GTA GTT226 GCC ATC TTG GCC ATG CAA GAA AAG AAA AGA AGG CAT TTA CTC TAT271 GTC GGG GGG CGG TAA TCG TGT GTT GCA TCG ATG CGT TTG TGG TCA316 CCA CGA AGA TGA GGA CCA ACT TGA AAA GAT TCC TGG GAG TCG AAG361 TTG AAA GGA AGC TTT CCC CCG CCA AGG ACG CCT ACC CCG AAA CCG406 GCC CCG ACG CCC CGC AGA GGC CCG CCT GAA GCC AGC CCG GCG CCC451 TAG CAG ATG CAC GTG TCT GTC GAA TCG CTG CCT CCG AGC CCA CCC496 CCG AGC TCG CAT GCT GTC ACC CAT TCC AGC CTA AAT GTG ACC ATA541 AAA TTA GGG CTG CTG CTT TTA TCG AGA AAA AAA AAA AAA AAA AAA586 AA
The information of SEQ ID NO:4
(ⅰ) sequence signature:
(I) length: 94 amino acid
(J) type: amino acid
(K) chain: strand
(L) topological framework: linearity
(ⅱ) molecule type: protein
(ⅲ) sequence description: SEQ ID NO:4
5 10 15 | | |?1?Met?Leu?Lys?Ile?Leu?Arg?Leu?Ser?Leu?Ile?Leu?Gly?Ala?Leu?Ala16?Cys?Phe?Ile?Ile?Thr?Gln?Ala?Asn?Glu?Ser?Phe?Ile?Thr?Ile?Thr31?Ser?Leu?Glu?Ile?Cys?Ile?Val?Val?Phe?Phe?Ile?Leu?Ile?Tyr?Val46?Leu?Thr?Leu?His?His?Leu?Leu?Thr?Tyr?Leu?His?Trp?Pro?Leu?Leu61?Asp?Leu?Thr?Asn?Ser?Ile?Ile?Thr?Ala?Val?Phe?Leu?Ser?Val?Val76?Ala?Ile?Leu?Ala?Met?Gln?Glu?Lys?Lys?Arg?Arg?His?Leu?Leu?Tyr91?Val?Gly?Gly?Arg
Claims (19)
1, one section isolating polynucleotide sequence, described nucleotide sequence comprises the member who is selected from the group of being made up of following sequence:
The polynucleotide sequence of (1) one section shown in SEQ ID NO:2 polypeptide of can encoding;
The polynucleotide sequence of (2) one sections shown in SEQ ID NO:4 polypeptide of can encoding;
Can hybridize with (1) or (2), and have the polynucleotide sequence of at least 70% homology for (3) one sections with them;
(4) one sections polynucleotide sequences, this sequence are the nucleic acid fragments of (1), (2) or (3).
2, one section isolating polynucleotide sequence, wherein said nucleotide sequence comprises the member who is selected from the group of being made up of following sequence:
(1) one section polynucleotide sequence, this sequence aminoacid sequence that mature polypeptide had that recombinant chou is expressed among the culture presevation CGMCC NO.0456.1 of can encoding;
(2) one sections polynucleotide sequences, this sequence aminoacid sequence that mature polypeptide had that recombinant chou is expressed among the culture presevation CGMCC NO.0456.2 of can encoding;
Can hybridize with (1) or (2), and have the polynucleotide sequence of at least 70% homology for (3) one sections with them;
(4) one sections polynucleotide sequences, this sequence are the nucleic acid fragments of (1), (2) or (3).
3, nucleotide sequence according to claim 1, polynucleotide wherein are DNA.
4, nucleotide sequence according to claim 1, polynucleotide wherein are RNA.
5, nucleotide sequence according to claim 1, polynucleotide wherein are genomic dnas.
6, according to the nucleotide sequence of claim 3, wherein said nucleotide sequence comprises the member who is selected from the group of being made up of following sequence:
(1) one section polynucleotide sequence shown in SEQ ID NO:1;
(2) one sections polynucleotide sequences shown in SEQ ID NO:3;
(3) one sections can with (1) or (2) hybridization, and have the polynucleotide sequence of at least 70% homology with them;
(4) one sections polynucleotide sequences, this sequence are the nucleic acid fragments of (1), (2) or (3).
7, according to the nucleotide sequence of claim 6, wherein said nucleotide sequence is shown in 1-450 position Nucleotide among the SEQ ID NO:1.
8, according to the nucleotide sequence of claim 6, wherein said nucleotide sequence is shown in 1-285 position Nucleotide among the SEQ ID NO:3.
9, a kind of carrier, this carrier comprises the nucleotide sequence of claim 6.
10, a kind of host cell, this host cell is through carrier conversion, the transfection of claim 9 or transduceed.
11, a kind of method of producing polypeptide with genetic engineering means, this method are included in the polypeptide of expressing in the host cell of claim 10 by described dna encoding.
12, a peptide species, this peptide species comprises the member who is selected from the group of being made up of following sequence:
(1) a kind of polypeptide with aminoacid sequence shown in SEQ ID NO:2;
(2) a kind of polypeptide with aminoacid sequence shown in SEQ ID NO:4;
(3) a kind of have with culture presevation CGMCC NO.0456.1 in the recombinant chou mature polypeptide of expressing have the polypeptide of same acid sequence;
(4) a kind of have with culture presevation CGMCC NO.0456.2 in the recombinant chou mature polypeptide of expressing have the polypeptide of same acid sequence;
(5) polypeptide fragment of a kind of (1), (2), (3) or (4) described polypeptide.
13, a kind of pharmaceutical composition, described pharmaceutical composition comprise the described polypeptide of the claim 12 of effective dose or its activeconstituents, and one or more pharmaceutically acceptable carrier or vehicle.
14, a kind of mono-clonal or polyclonal antibody, described antibody can combine with the described polypeptide of claim 12 specifically.
15, a kind of antagonist, described antagonist can suppress or seal the biological activity of the described polypeptide of claim 12.
16, a kind of activator, described activator can activate the biological activity of the described polypeptide of claim 12.
17, the purposes of the described polypeptide of claim 12 in the pharmaceutical composition of preparation treatment hemopoietic system and disease of immune system.
18, according to the purposes of claim 17, described purposes is the purposes of polypeptide in the pharmaceutical composition of preparation treatment hemopoietic system of claim 12.
19, according to the purposes of claim 17, described purposes is the purposes of polypeptide in the immune pharmaceutical composition of preparation treatment of claim 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001210270A CN1219057C (en) | 2000-07-13 | 2000-07-13 | Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001210270A CN1219057C (en) | 2000-07-13 | 2000-07-13 | Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1283693A true CN1283693A (en) | 2001-02-14 |
| CN1219057C CN1219057C (en) | 2005-09-14 |
Family
ID=4588540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001210270A Expired - Fee Related CN1219057C (en) | 2000-07-13 | 2000-07-13 | Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1219057C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101161283B (en) * | 2006-10-10 | 2012-07-11 | 北京大学 | New applications of CMTM1-v17 and its antagonists |
-
2000
- 2000-07-13 CN CNB001210270A patent/CN1219057C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101161283B (en) * | 2006-10-10 | 2012-07-11 | 北京大学 | New applications of CMTM1-v17 and its antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1219057C (en) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1143372A (en) | hematopoietic maturation factor | |
| CN1321745A (en) | Macrophage inflammatory protein -3, -4 and -1 gamma | |
| CN1142188A (en) | human growth hormone | |
| CN1086543A (en) | Clones coding has the cDNA of people's graininess scavenger cell and eosinophie cellular growth active polypeptide | |
| JP2001501813A (en) | Secreted proteins and polynucleotides encoding them | |
| JP2008154583A (en) | Interleukin-1 related gene and protein | |
| CN1198186A (en) | short form of chemokine beta-8 | |
| CN1219057C (en) | Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB | |
| CN1244584A (en) | Chemotarix factor with immunocyte chemotaxis and hemopoinesis stimulating activity | |
| CN1369561A (en) | Cell factor CK-HA and its variant with hematogenesis promoting and immunoregulating functions | |
| CN1343725A (en) | Human angiogenin-like protein and coding sequence and application thereof | |
| CN1218833A (en) | Polypeptide with cell withering promoting activity | |
| CN1313297A (en) | Human protein able to suppress growth of cancer cells and its coding sequence | |
| CN1299823A (en) | New human cell factor and its code sequence and use | |
| CN1297922A (en) | Human calcium binding S100 protein 21 as one kind of polypeptide and polynucleotides encoding this polypeptide | |
| CN1288056A (en) | Novel human coagulation thrombus protein-1 media factor, the application and prepn. method therefor | |
| CN1388132A (en) | Cell death inducing protein and its coding sequence and use | |
| CN1167490A (en) | Human stanniocalcin-alpha | |
| CN1342713A (en) | Human macrobiosis-ensuring protein and its coding sequence and application | |
| CN1470524A (en) | Polypeptide-human transcriptional elongation factor IIS51 and polynucleotide encoding this polypeptide | |
| CN1323803A (en) | New human protein with the function of inhibiting cancer cell growth and its coding sequence | |
| CN1470525A (en) | Polypeptide-human SEH protein 29 and polynucleotide encoding this polypeptide | |
| CN1299828A (en) | New cell factor acceptor and its code sequence and use | |
| CN1201831A (en) | A method for preparing recombinant human growth-stimulating hormone-releasing factor | |
| CN1477193A (en) | Novel human Rab GTP enzyme, its coding sequence and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050914 |